Literature DB >> 33070275

Engrafted primary type-2 astrocytes improve the recovery of the nigrostriatal pathway in a rat model of Parkinson's disease.

Yanyun Sun1, Xiao-Jun Lu2, Xinghui Fu1, Ye Zhang1, Yan Zhan1, Jiabing Liu1, Lingxia Zhao1, Chun-Lin Xia3.   

Abstract

Parkinson's disease (PD) is a disorder characterized by a progressive loss of the dopaminergic neurons in the substantia nigra and a depletion of the neurotransmitter dopamine in the striatum. Our published results indicate that fasciculation and elongation protein zeta-1 (FEZ1) plays a role in the astrocyte-mediated protection of dopamine neurons and regulation of the neuronal microenvironment during the progression of PD. In this study, we examined the effects of engrafted type-2 astrocytes (T2As) with high expression of FEZ1 on the improvement of the symptoms and functional reconstruction of PD rats. T2As were stereotactically transplanted into the striatum of rats with PD induced by 6-hydroxydopamine (6-OHDA). An examination of apomorphine (APO)-induced rotations was performed to evaluate dopamine neuron damage and motor functions. Remarkably, the grafted cells survived in the lesion environment for six weeks or longer after implantation. In addition, the transplantation of T2As decrease the average velocity and the duration time of the APO-induced rotations, and increase the actuation time, as measured in the rotation behavioural tests. In the substantia nigra, the transplantation of T2As reduced the PD-induced GFAP, TH and FEZ1 downregulation. The grafted cells exclusively migrated to other regions near the injection site in the striatum and differentiated into GFAP+ astrocytes or TH+ neurons. Furthermore, by detecting monoamine neurotransmitters through high-performance liquid chromatography, we found that the nigrostriatal pathway had been repaired to some extent. Taken together, these results suggest that engrafted T2As with high expression of FEZ1 improved the symptoms and functional reconstruction of PD rats, providing a theoretical basis for FEZ1 as a potential target and engraftment of T2As as a therapeutic strategy in the treatment of PD.

Entities:  

Keywords:  FEZ1; Monoamine neurotransmitter; Nigrostriatal pathway; Parkinson’s disease; Type-2 astrocytes

Mesh:

Substances:

Year:  2020        PMID: 33070275     DOI: 10.1007/s11010-020-03931-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  36 in total

1.  Mice with reduced vesicular monoamine storage content display nonmotor features of Parkinson's disease.

Authors:  Anthony C Vernon
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

2.  Neuropsychological changes following deep brain stimulation surgery for Parkinson's disease: comparisons of treatment at pallidal and subthalamic targets versus best medical therapy.

Authors:  Johannes C Rothlind; Michele K York; Kim Carlson; Ping Luo; William J Marks; Frances M Weaver; Matthew Stern; Kenneth Follett; Domenic Reda
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-09-02       Impact factor: 10.154

3.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

Authors:  M G Spillantini; R A Crowther; R Jakes; M Hasegawa; M Goedert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.

Authors:  Silvia Picazio; Viviana Ponzo; Carlo Caltagirone; Livia Brusa; Giacomo Koch
Journal:  J Neurol       Date:  2018-07-06       Impact factor: 4.849

Review 5.  Parkinson's disease: Mechanisms, translational models and management strategies.

Authors:  Chand Raza; Rabia Anjum; Noor Ul Ain Shakeel
Journal:  Life Sci       Date:  2019-04-10       Impact factor: 5.037

Review 6.  Structural genomic variations and Parkinson's disease.

Authors:  Sara Bandrés-Ciga; Clara Ruz; Francisco J Barrero; Francisco Escamilla-Sevilla; Javier Pelegrina; Francisco Vives; Raquel Duran
Journal:  Minerva Med       Date:  2017-05-25       Impact factor: 4.806

7.  Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

Authors:  E R Dorsey; R Constantinescu; J P Thompson; K M Biglan; R G Holloway; K Kieburtz; F J Marshall; B M Ravina; G Schifitto; A Siderowf; C M Tanner
Journal:  Neurology       Date:  2006-11-02       Impact factor: 9.910

Review 8.  Emerging therapies in Parkinson disease - repurposed drugs and new approaches.

Authors:  Ahmad Elkouzi; Vinata Vedam-Mai; Robert S Eisinger; Michael S Okun
Journal:  Nat Rev Neurol       Date:  2019-04       Impact factor: 42.937

Review 9.  Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?

Authors:  K Ray Chaudhuri; Alexandra Rizos; Kapil D Sethi
Journal:  J Neural Transm (Vienna)       Date:  2013-03-02       Impact factor: 3.575

10.  Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications.

Authors:  Massimo S Fiandaca; Krystof S Bankiewicz; Howard J Federoff
Journal:  Pharmaceuticals (Basel)       Date:  2012-06-04
View more
  1 in total

Review 1.  Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted α-synuclein and genetic modulation.

Authors:  Changjing Wang; Tongtong Yang; Meiyu Liang; Junxia Xie; Ning Song
Journal:  Transl Neurodegener       Date:  2021-10-18       Impact factor: 8.014

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.